- funded by IMI-JU
- 01 March 2011 - 31 August 2016
- 11 EFPIA members
- 10 Academia and 5 SME's
- Total cost € 23,032,609
Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.
As part of the Pharma Research and Early Development (pRED) department, the Roche Modeling and simulation group is working in developing models using drug/disease data to support the drug development and improve the individual treatment strategy. In order to promote the concept of Model-Based Drug Development, this group is working closely with other In-Silico groups to develop disease and translational models and also with the informatics department to perform tests of new software and innovative techniques. This group brings into the IMI project its broad knowledge on model development on large clinical databases in order to describe both disease and drug effect through physiological pathways in different disease areas.